EU fines pharma firms over generics delay (Update)

European Commissioner for Competition, Joaquin Almunia, addresses the media, at the European Commission headquarters in Brussels, Wednesday, June 19, 2013. The European Union says it has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives to a major antidepressant to capitalize profit at the expense of patients. (AP Photo/Yves Logghe)

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives to a major antidepressant.

The EU claimed that the companies sought to capitalize profit at the expense of patients.

EU Antitrust Commissioner Joaquin Almunia said Wednesday that Lundbeck alone was fined 93.8 million euros ($125.6 million) for anti-competitive behavior, charging it agreed with several companies to delay the entry of generic versions of its antidepressant citalopram.

Lundbeck immediately announced it would appeal the fine and insisted it did not unduly restrict competition.

Almunia's decisions came only days after the U.S. supreme court said that "pay-for-delay" deals between pharmaceutical corporations and generic drug companies can sometimes be illegal and challenged in court.

Almunia took a similar line for the 27-nation EU.

"It is unacceptable that a company pays off its competitors to stay out of its market and delay the entry of cheaper medicines," Almunia said. "We are confirming that the so-called 'pay for delay' deals constitute severe infringements."

Even though the beginning of the case stems from 2002, Almunia said such practices were especially painful during years of economic crisis when EU nations need to tighten their budgets. Traditionally, health care is a huge draw on expenses.

"Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints," he said.

He said that prices in Britain for the generic version of citalopram fell 90 percent compared to Lundbeck's price once the generic market entry finally took place.

EU officials are investigating three similar cases but Almunia said he had "the impression that the anti-competitive practices have been reduced" since an initial inquiry into the sector in 2009.

In the case of Lundbeck, the EU said that four major generic producers agreed not to enter the market, getting "tens of millions of euros" in return. It said that company documents referred to a "club" which would share "a pile of $$$," adding that Lundbeck also bought generic stock only to destroy it.

Such practices go against the core purpose of generic medicine, Almunia said.

"It is therefore crucial that the European citizens are not deprived of cheaper health bills by anticompetitive practices," he said.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Lundbeck profit jumps but warns on generic pressure

May 01, 2013

Danish pharmaceutical company Lundbeck Wednesday posted a higher than expected quarterly net profit, helped by the expansion of an alliance with Japan's Otsuka and the divestment of a US portfolio of non-core products.

EU decision on Microsoft probe close: commissioner

Dec 20, 2012

The European Commission said Thursday it is close to a decision in its investigation of US giant Microsoft and its failure to provide clients with a choice of Web browser, as it had promised to do.

EU 'looking at' Apple practices following queries

Mar 22, 2013

European Union competition watchdogs said Friday they were "looking into" potential anti-trust issues at iPad and iPhone giant Apple, following queries raised by telecommunications operators.

EU launches probe into suspected chipmaker cartel

Apr 22, 2013

EU anti-trust authorities announced on Monday a formal cartel probe into smartcard chipmakers—the motors for everything from bank and mobile SIM cards to electronic ID papers, after talks aimed at securing ...

Recommended for you

Experts want restrictions on testosterone drug use (Update)

2 hours ago

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

Big cities take aim at prescription painkillers

Sep 16, 2014

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.

World Health Organization policy improves use of medicines

Sep 16, 2014

In this issue of PLOS Medicine, Kathleen Holloway from WHO and David Henry (University of Toronto, Canada) evaluated data on reported adherence to WHO essential medicines practices and measures of quality use of medicines from 5 ...

User comments